Interleukin Genetics, Inc. to Present at Biotech Showcase 2011

WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTC QB: ILIU) announced today that CEO Lewis H. Bender will present at the Biotech Showcase 2011, taking place at the Parc 55 Wyndham San Francisco, January 10-12, 2011.  The corporate presentation will include a company overview highlighting its business opportunities and is scheduled for Monday, January 10 at 3:45 p.m. in the Mission II room.  

Company management will be available for one-on-one meetings with investors participating in the Biotech Showcase.  A webcast of Mr. Bender's presentation will be available on the Company's Investor Relations section of the Website and will be accessible for 30 days. 

About Interleukin Genetics

Interleukin Genetics, Inc. (OTC QB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand.  The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA).  For more information please visit www.ilgenetics.com.

SOURCE Interleukin Genetics, Inc.